[
  {
    "ts": null,
    "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=6fb7a7605ba70cebb835d00b4051b34da1fb4a4b08e8fd2015a7f1d1d3c1b205",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735835580,
      "headline": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "id": 132321546,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly & Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=6fb7a7605ba70cebb835d00b4051b34da1fb4a4b08e8fd2015a7f1d1d3c1b205"
    }
  },
  {
    "ts": null,
    "headline": "Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst",
    "summary": "According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to overtake competitors.",
    "url": "https://finnhub.io/api/news?id=e2ca9bd82ac09b26edfda8f132dcd6094c27d763c07ace0812903fa9facd8435",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735833900,
      "headline": "Zepbound will dominate obesity market following SURMOUNT-5 results, says analyst",
      "id": 132240321,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/22/2025/01/shutterstock_2554381493.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to overtake competitors.",
      "url": "https://finnhub.io/api/news?id=e2ca9bd82ac09b26edfda8f132dcd6094c27d763c07ace0812903fa9facd8435"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Upgraded to \"Buy\" as Analysts Boost Price Target to $1,250",
    "summary": "Eli Lilly's Strong Pipeline and Earnings Lead to Stock Upgrade and Higher Price Target",
    "url": "https://finnhub.io/api/news?id=1147bbe66e946a6b89412eb1c2b36fc0692333c2255b1c18359121a77fa341d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735830414,
      "headline": "Eli Lilly Stock Upgraded to \"Buy\" as Analysts Boost Price Target to $1,250",
      "id": 132244763,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/ff347577c1c0d2cd942b9399fde6bc37",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's Strong Pipeline and Earnings Lead to Stock Upgrade and Higher Price Target",
      "url": "https://finnhub.io/api/news?id=1147bbe66e946a6b89412eb1c2b36fc0692333c2255b1c18359121a77fa341d1"
    }
  },
  {
    "ts": null,
    "headline": "US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report",
    "summary": "Eli Lilly and Co.'s (NYSE:LLY) Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) Wegovy (semaglutide) for market dominance. According to a GlobalData report, Zepbound's superior effectiveness and strategic market growth position it to potentially overtake Wegovy as the leading therapy for obesity. Since its debut, Zepbound has expanded its scope beyond obesity treatment. In December 2024, the FDA approved the drug for tre",
    "url": "https://finnhub.io/api/news?id=6f17fc6ed29c9b2abaa786d74436d743a10e06357b73844515fd84095fddde65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735827620,
      "headline": "US Employer Health Costs To Rise In 2025 Fueled By Weight Loss: Report",
      "id": 132240322,
      "image": "https://media.zenfs.com/en/Benzinga/28651aca72ad191fcfd8ef45a71f5d29",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Co.'s (NYSE:LLY) Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) Wegovy (semaglutide) for market dominance. According to a GlobalData report, Zepbound's superior effectiveness and strategic market growth position it to potentially overtake Wegovy as the leading therapy for obesity. Since its debut, Zepbound has expanded its scope beyond obesity treatment. In December 2024, the FDA approved the drug for tre",
      "url": "https://finnhub.io/api/news?id=6f17fc6ed29c9b2abaa786d74436d743a10e06357b73844515fd84095fddde65"
    }
  },
  {
    "ts": null,
    "headline": "5 Large Drug Stocks to Keep An Eye On in the New Year",
    "summary": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.",
    "url": "https://finnhub.io/api/news?id=5c4e85b9cdfce8579155e19b652e5590cfd40b26b8a07a3e0ca3dfb27a46213a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735825260,
      "headline": "5 Large Drug Stocks to Keep An Eye On in the New Year",
      "id": 132242207,
      "image": "https://media.zenfs.com/en/zacks.com/5d5a6eb884ce28277f39a4369974b5ea",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), AbbVie (ABBV), AstraZeneca (AZN) and Pfizer (PFE) are worth retaining in one's portfolio.",
      "url": "https://finnhub.io/api/news?id=5c4e85b9cdfce8579155e19b652e5590cfd40b26b8a07a3e0ca3dfb27a46213a"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy the Dip in Novo Nordisk Stock Right Now?",
    "summary": "Shares of Novo Nordisk are in free fall following lackluster results from a new clinical trial.",
    "url": "https://finnhub.io/api/news?id=e74a9859f52fada3d948b2103c9b20b303180d425abdccd28416f6ee3210e876",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735824600,
      "headline": "Should You Buy the Dip in Novo Nordisk Stock Right Now?",
      "id": 132240323,
      "image": "https://g.foolcdn.com/editorial/images/802438/semaglutide-medication-in-box.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares of Novo Nordisk are in free fall following lackluster results from a new clinical trial.",
      "url": "https://finnhub.io/api/news?id=e74a9859f52fada3d948b2103c9b20b303180d425abdccd28416f6ee3210e876"
    }
  },
  {
    "ts": null,
    "headline": "Tirzepatide outpacing Wegovy in the obesity space",
    "summary": "Novo Nordisk’s Wegovy made a significant impact on the obesity market when it launched in 2021.",
    "url": "https://finnhub.io/api/news?id=9d45247d8920d9828e3e7d00f58cb5ba59a22fb26739323971c3533e8deda52e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735821654,
      "headline": "Tirzepatide outpacing Wegovy in the obesity space",
      "id": 132238336,
      "image": "https://live-b2b-gdm-figaro1.pantheonsite.io/wp-content/uploads/sites/24/2025/01/Obesity-CW-feat-img.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk’s Wegovy made a significant impact on the obesity market when it launched in 2021.",
      "url": "https://finnhub.io/api/news?id=9d45247d8920d9828e3e7d00f58cb5ba59a22fb26739323971c3533e8deda52e"
    }
  },
  {
    "ts": null,
    "headline": "Can Eli Lilly and Company (NYSE:LLY) Maintain Its Strong Returns?",
    "summary": "One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...",
    "url": "https://finnhub.io/api/news?id=4896bc93f226e23492fb82569ca8740d6227a84fffe369be9d8fedacdd745873",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735819226,
      "headline": "Can Eli Lilly and Company (NYSE:LLY) Maintain Its Strong Returns?",
      "id": 132244768,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/1b6847ee48493a5698212be177362a15",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...",
      "url": "https://finnhub.io/api/news?id=4896bc93f226e23492fb82569ca8740d6227a84fffe369be9d8fedacdd745873"
    }
  },
  {
    "ts": null,
    "headline": "Weight loss drugs are changing the game, Eli Lilly exec says — but many still can't get them",
    "summary": "Obesity is a major global health crisis, especially in the United States, but newer weight-loss drugs like Eli Lilly’s (LLY) Zepbound could offer a long-awaited solution — if they become more accessible.",
    "url": "https://finnhub.io/api/news?id=14dadf273589e5b576301e15f55c2250b99dc1888043cfec6c91be599834d089",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735812000,
      "headline": "Weight loss drugs are changing the game, Eli Lilly exec says — but many still can't get them",
      "id": 132238017,
      "image": "https://media.zenfs.com/en/quartz.com/8e1c360ef43ea128d9e7f031bdda9e00",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Obesity is a major global health crisis, especially in the United States, but newer weight-loss drugs like Eli Lilly’s (LLY) Zepbound could offer a long-awaited solution — if they become more accessible.",
      "url": "https://finnhub.io/api/news?id=14dadf273589e5b576301e15f55c2250b99dc1888043cfec6c91be599834d089"
    }
  },
  {
    "ts": null,
    "headline": "INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025",
    "summary": "INmune Bio's XPro shows promising results in Alzheimer's, with Phase 2 data expected in 2025, potential for big pharma interest. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=bc8999ff4d784640f56044fffee39ca79cfd114343de1d0c1866ae64ea740323",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735807968,
      "headline": "INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025",
      "id": 132238619,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1554047481/image_1554047481.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "INmune Bio's XPro shows promising results in Alzheimer's, with Phase 2 data expected in 2025, potential for big pharma interest. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=bc8999ff4d784640f56044fffee39ca79cfd114343de1d0c1866ae64ea740323"
    }
  },
  {
    "ts": null,
    "headline": "After Two Stellar Years for Stocks, It’s Time to Play Defense",
    "summary": "After Two Stellar Years for Stocks, It’s Time to Play Defense",
    "url": "https://finnhub.io/api/news?id=49a790483329cc55d77172f258673847008f44f86733642555225aaa8f4660c7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1735783200,
      "headline": "After Two Stellar Years for Stocks, It’s Time to Play Defense",
      "id": 132321547,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "After Two Stellar Years for Stocks, It’s Time to Play Defense",
      "url": "https://finnhub.io/api/news?id=49a790483329cc55d77172f258673847008f44f86733642555225aaa8f4660c7"
    }
  }
]